A Phase 2, Double-Blind, Placebo-Controlled Study of Benralizumab (KHK4563) in Patients With Eosinophilic Chronic Rhinosinusitis
Latest Information Update: 19 Nov 2021
Price :
$35 *
At a glance
- Drugs Benralizumab (Primary)
- Indications Rhinosinusitis
- Focus Therapeutic Use
- Sponsors Kyowa Hakko Kirin; Kyowa Kirin
- 01 Nov 2021 Primary endpoint (The change from baseline in nasal polyp score at Week 12) has not been met as per the results published in the American Journal of Rhinology and Allergy
- 01 Nov 2021 Results published in the American Journal of Rhinology and Allergy
- 20 Apr 2018 Status changed from active, no longer recruiting to completed.